A Study of the Pharmacokinetic and Safety Profile of QID Dosing of Mibefradil in Normal Human Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Mibefradil (Primary)
- Indications Glioblastoma; Glioma; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Cavion
- 11 Jul 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2012 Additional trial identifier NCT01550458 and investigators identified, inclusion-exclusion criteria amended as reported by ClinicalTrials.gov.